{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:00:23Z","timestamp":1791961223376,"version":"4.3.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtha.2024.06.022","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T02:27:49Z","timestamp":1726712869000},"page":"2939-2941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hemophilia prophylaxis: defining outcome measures by regulatory agencies and ISTH"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3995-4018","authenticated-orcid":false,"given":"Nathan","family":"Visweshwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmel","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Jaglal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.06.022_bib1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1055\/s-0040-1709519","article-title":"Modeling to predict factor VIII levels associated with zero bleeds in patients with severe hemophilia A initiated on tertiary prophylaxis","volume":"120","author":"Chowdary","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.022_bib2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/hae.14803","article-title":"Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: a systematic literature review","volume":"29","author":"Mannucci","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.06.022_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.06.022_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.06.022_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.thromres.2017.05.038","article-title":"Modifiers of clinical phenotype in severe congenital hemophilia","volume":"156","author":"Franchini","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.06.022_bib6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood.V124.21.689.689","article-title":"Modeling minimally-effective FVIII trough levels in hemophilia a patients on PK-guided prophylaxis","volume":"14","author":"Spotts","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.022_bib7","first-page":"e208","article-title":"Assessments of outcome in haemophilia\u2014a patient perspective","volume":"22","author":"O\u2019Mahony","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.06.022_bib8","article-title":"Human gene therapy for hemophilia","year":"2020","journal-title":"Guidance for industry"},{"issue":"Suppl 3","key":"10.1016\/j.jtha.2024.06.022_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.14099","article-title":"Outcome measures in haemophilia: beyond ABR (annualized bleeding rate)","volume":"27","author":"Manco-Johnson","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.06.022_bib11","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.022_bib12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/cts.12794","article-title":"Annual bleeding rates: pitfalls of clinical trial outcomes in hemophilia patients","volume":"13","author":"Keipert","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.06.022_bib13","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1182\/blood-2021-150822","article-title":"Baseline VWF:Ag level and body mass index are inverse influencing factors of annualized total bleeding rate and annualized joint bleeding rate respectively in severe-type adult patients with hemophilia a (PwHA) with episodic treatment with rFVIII","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.022_bib14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtha.2023.01.035","article-title":"Magnetic resonance imaging evidence for subclinical joint bleeding in a Dutch population of people with severe hemophilia on prophylaxis","volume":"21","author":"van Leeuwen","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.022_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1365-2516.2008.01876.x","article-title":"Changing patterns of bleeding in patients with severe haemophilia A","volume":"15","author":"Stephensen","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.06.022_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/hae.13313","article-title":"Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies","volume":"23","author":"Pierce","year":"2017","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624003830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:46:06Z","timestamp":1759351566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624003830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1538783624003830"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.022","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemophilia prophylaxis: defining outcome measures by regulatory agencies and ISTH","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}